- Home
- FRD vs COYA Comparison
FRD vs COYA Comparison
Compare FRD & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- COYA
- Stock Information
- Founded
- FRD 1965
- COYA 2020
- Country
- FRD United States
- COYA United States
- Employees
- FRD N/A
- COYA 8
- Industry
- FRD Steel/Iron Ore
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- COYA Health Care
- Exchange
- FRD Nasdaq
- COYA Nasdaq
- Market Cap
- FRD 122.0M
- COYA 92.2M
- IPO Year
- FRD N/A
- COYA 2022
- Fundamental
- Price
- FRD $17.00
- COYA $6.60
- Analyst Decision
- FRD
- COYA Strong Buy
- Analyst Count
- FRD 0
- COYA 4
- Target Price
- FRD N/A
- COYA $17.00
- AVG Volume (30 Days)
- FRD 24.4K
- COYA 78.2K
- Earning Date
- FRD 06-10-2025
- COYA 05-08-2025
- Dividend Yield
- FRD 0.94%
- COYA N/A
- EPS Growth
- FRD N/A
- COYA N/A
- EPS
- FRD 0.81
- COYA N/A
- Revenue
- FRD $447,616,000.00
- COYA $3,554,061.00
- Revenue This Year
- FRD N/A
- COYA $94.45
- Revenue Next Year
- FRD N/A
- COYA N/A
- P/E Ratio
- FRD $20.62
- COYA N/A
- Revenue Growth
- FRD N/A
- COYA N/A
- 52 Week Low
- FRD $12.24
- COYA $4.65
- 52 Week High
- FRD $19.47
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- FRD 61.76
- COYA 49.48
- Support Level
- FRD $14.26
- COYA $5.06
- Resistance Level
- FRD $17.24
- COYA $5.60
- Average True Range (ATR)
- FRD 1.02
- COYA 0.56
- MACD
- FRD 0.31
- COYA 0.03
- Stochastic Oscillator
- FRD 95.20
- COYA 60.57
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.